UroGen Pharma Ltd URGN
$27.65 −$4.08 (-12.86%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.65 0.00%
Open$31.15
Prev close$31.73
Day range$27.57 – $31.90
Volume2.40M
Market cap$1.36B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$89.00M+223.9% YoY
Operating profit$8.33M+130.4% YoY
Net profit-$1.46M+95.6% YoY
Diluted EPS-$0.03+95.7% YoY
Free cash flow-$15.27M+63.9% YoY
Operating cash flow-$15.20M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin91.4%
Operating margin-12.4%
Net margin-26.3%
Return on assets-28.8%
Current ratio3.40
Liabilities / assets146.1%
Cash & investments$90.55M
Total debt$194.12M
Net cash (debt)-$103.57M
Where the revenue comes from
Quarter 2026/Q3
By business line
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $89.00M | $72.46M | $50.96M | $109.79M | $37.84M |
| Total Operating Revenue | $89.00M | $72.46M | $50.96M | $109.79M | $37.84M |
| Cost of Revenue | $7.50M | $6.57M | $4.14M | $12.45M | $3.29M |
| Gross Profit | $81.50M | $65.88M | $46.82M | $97.34M | $34.55M |
| Operating Expense | $73.17M | $65.77M | $67.08M | $222.20M | $53.66M |
| Selling and Admin Expenses | $47.21M | $48.44M | $51.49M | $155.10M | $39.35M |
| Research & Development | $25.96M | $17.34M | $15.60M | $67.11M | $14.31M |
| Operating Profit | $8.33M | $111,000.00 | -$20.26M | -$124.86M | -$19.12M |
| Net Non-Operating Interest Income (Expense) | -$8.70M | -$8.49M | -$7.76M | -$27.88M | -$7.52M |
| Non-Operating Interest Income | $681,000.00 | $946,000.00 | $931,000.00 | $5.97M | $908,000.00 |
| Non-Operating Interest Expense | $4.84M | $4.89M | $4.19M | $15.35M | $3.77M |
| Total Other Finance Costs | $4.55M | $4.55M | $4.51M | $18.50M | $4.66M |
| Other Income (Expense) | -$74,000.00 | -$347,000.00 | -$323,000.00 | -$670,000.00 | -$5,000.00 |
| Other Non-Operating Income (Expenses) | -$74,000.00 | -$347,000.00 | -$323,000.00 | -$670,000.00 | -$5,000.00 |
| Pretax Profit | -$446,000.00 | -$8.72M | -$28.35M | -$153.42M | -$26.64M |
| Tax | $1.02M | $5.63M | -$4.77M | $78,000.00 | -$275,000.00 |
| Net Profit | -$1.46M | -$14.35M | -$23.57M | -$153.49M | -$26.36M |
| Profit from Continuing Operations | -$1.46M | -$14.35M | -$23.57M | -$153.49M | -$26.36M |
| Net Income to Parent Company | -$1.46M | -$14.35M | -$23.57M | -$153.49M | -$26.36M |
| Net Income to Common Stockholders | -$1.46M | -$14.35M | -$23.57M | -$153.49M | -$26.36M |
| Basic EPS | -$0.03 | -$0.28 | -$0.47 | -$3.19 | -$0.54 |
| Diluted EPS | -$0.03 | -$0.28 | -$0.47 | -$3.19 | -$0.54 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $271.87M | $252.59M | $253.69M | $200.46M | $200.46M |
| Total Current Assets | $251.90M | $235.43M | $237.46M | $186.02M | $186.02M |
| Cash and Cash Equivalents & Short-Term Investments | $90.55M | $107.98M | $140.27M | $120.46M | $120.46M |
| -Cash and Cash Equivalents | $85.56M | $79.13M | $109.97M | $110.75M | $110.75M |
| -Short Term Investments | $4.99M | $28.84M | $30.31M | $9.71M | $9.71M |
| Receivables | $117.28M | $88.76M | $55.41M | $33.08M | $33.08M |
| -Accounts Receivable | $117.28M | $88.76M | $55.41M | $33.08M | $33.08M |
| Inventory | $25.15M | $24.59M | $20.92M | $16.46M | $16.46M |
| Restricted Cash | $1.33M | $1.33M | $1.33M | $1.35M | $1.35M |
| Other Current Assets | $17.58M | $12.78M | $19.53M | $14.67M | $14.67M |
| Total Non-Current Assets | $19.98M | $17.16M | $16.23M | $14.43M | $14.43M |
| Net PPE | $7.94M | $8.23M | $8.56M | $9.09M | $9.09M |
| -Gross PPE | $12.76M | $12.97M | $13.22M | $13.68M | $13.68M |
| -Accumulated Depreciation | -$4.82M | -$4.74M | -$4.66M | -$4.59M | -$4.59M |
| Other Non-Current Assets | $12.04M | $8.94M | $7.67M | $5.34M | $5.34M |
| Total Liabilities | $397.09M | $384.99M | $377.94M | $305.93M | $305.93M |
| Total Current Liabilities | $74.03M | $61.92M | $50.64M | $46.42M | $46.42M |
| Payables | $17.26M | $15.47M | $17.21M | $12.14M | $12.14M |
| -Accounts Payable | $17.26M | $15.47M | $17.21M | $12.14M | $12.14M |
| Current Accrued Expenses | $29.58M | $24.47M | $18.14M | $15.58M | $15.58M |
| Short-Term Debt and Capital Lease Obligation | $2.16M | $2.10M | – | – | – |
| -Current Capital Lease Obligation | $2.16M | $2.10M | – | – | – |
| Other Current Liabilities | $8.14M | $7.62M | $5.45M | $5.19M | $5.19M |
| Total Non-Current Liabilities | $323.06M | $323.07M | $327.31M | $259.51M | $259.51M |
| Long Term Accounts Payable and Other Payables | $3.90M | $3.90M | $3.90M | $3.90M | $3.90M |
| Long Term Debt and Capital Lease Obligation | $194.12M | $194.03M | $195.18M | $128.33M | $128.33M |
| -Long Term Debt | $189.35M | $188.73M | $189.53M | $122.21M | $122.21M |
| -Long Term Capital Lease Obligation | $4.77M | $5.30M | $5.65M | $6.12M | $6.12M |
| Derivative Product Liabilities | $125.03M | $125.14M | $128.23M | $127.28M | $127.28M |
| Total Equity | -$125.22M | -$132.40M | -$124.25M | -$105.47M | -$105.47M |
| Stockholders' Equity | -$125.22M | -$132.40M | -$124.25M | -$105.47M | -$105.47M |
| Capital Stock | $135,000.00 | $135,000.00 | $134,000.00 | $133,000.00 | $133,000.00 |
| -Common Stock | $135,000.00 | $135,000.00 | $134,000.00 | $133,000.00 | $133,000.00 |
| Additional Paid-In Capital | $873.75M | $865.11M | $858.90M | $854.09M | $854.09M |
| Retained Earnings | -$999.10M | -$997.64M | -$983.29M | -$959.72M | -$959.72M |
| Gains/Losses Not Affecting Retained Earnings | -$1,000.00 | -$2,000.00 | $8,000.00 | $19,000.00 | $19,000.00 |
| Investments and Advances | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$15.20M | -$33.01M | -$45.32M | -$162.44M | -$38.33M |
| Net cash flow from continuing operations | -$15.20M | -$33.01M | -$45.32M | -$162.44M | -$38.33M |
| Net Income from Continuing Operations | -$1.46M | -$14.35M | -$23.57M | -$153.49M | -$26.36M |
| Gain/Loss from Continuing Operations | $423,000.00 | $991,000.00 | $1.06M | $2.87M | $1.27M |
| Depreciation & Depletion & Amortization | $694,000.00 | $668,000.00 | $652,000.00 | $2.41M | $679,000.00 |
| Other Non-Cash Items | $620,000.00 | -$796,000.00 | $1.97M | $3.60M | $99,000.00 |
| Change in Working Capital | -$21.65M | -$24.57M | -$30.08M | -$27.91M | -$17.06M |
| -Change in Receivables | -$28.53M | -$33.35M | -$22.33M | -$12.78M | -$13.38M |
| -Change in Inventory | -$561,000.00 | -$3.67M | -$4.46M | -$7.24M | -$8.12M |
| -Change in Prepaid Assets | -$4.81M | $6.75M | -$4.86M | -$5.83M | -$2.55M |
| -Change in Payables and Accrued Expense | $11.53M | $7.02M | $3.95M | $3.23M | $3.95M |
| -Change in Other Current Assets | $904,000.00 | -$1.27M | -$2.33M | -$4.57M | $1.60M |
| -Change in Other Current Liabilities | -$190,000.00 | -$60,000.00 | -$53,000.00 | -$729,000.00 | $1.44M |
| -Change In Other Working Capital | $0.00 | – | – | -$1,000.00 | $0.00 |
| Net cash flow from investing | $19.85M | $1.67M | -$20.69M | $61.56M | $27.72M |
| Net Cash Flow from Continuing Investing Activities | $19.85M | $1.67M | -$20.69M | $61.56M | $27.72M |
| Net PPE Purchase and Sale | -$72,000.00 | -$60,000.00 | -$54,000.00 | -$289,000.00 | -$17,000.00 |
| Net Investment Purchase and Sale | $19.93M | $1.73M | -$20.63M | $61.85M | $27.73M |
| Financing Cash Flow | $1.78M | $500,000.00 | $65.20M | $39.92M | $31.32M |
| Net Cash Flow from Continuing Financing Activities | $1.78M | $500,000.00 | $65.20M | $39.92M | $31.32M |
| Net Issuance Payments Of Debt | -$616,000.00 | -$387,000.00 | $65.03M | -$1.86M | -$1.86M |
| Proceeds from Stock Option Exercised | $2.39M | $887,000.00 | $179,000.00 | $1.97M | $1.34M |
| Ending Cash Balance | $86.90M | $80.46M | $111.30M | $112.10M | $112.10M |
| Net Change in Cash | $6.43M | -$30.83M | -$800,000.00 | -$60.97M | $20.71M |
| Beginning Cash Balance | $80.46M | $111.30M | $112.10M | $173.06M | $91.39M |
| Free Cash Flow | -$15.27M | -$33.07M | -$45.37M | -$162.73M | -$38.34M |
| Net Common Stock Issuance | – | – | $0.00 | $39.80M | $31.83M |
No comments yet — be the first to weigh in on URGN.
Sign in to join the discussion.